Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyBCBS Illinois Biomarker Policy Update | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IllinoisPolicy RPLAB046

    Biomarkers for Myocardial Infarction and Chronic Heart Failure

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Illinois Policy RPLAB046 alerts

    Get alerted when Policy RPLAB046 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs reimbursement for laboratory biomarkers used to evaluate acute coronary syndrome, myocardial infarction, and chronic heart failure. It applies to providers submitting claims for eligible members, subject to the applicable Plan document and product-specific requirements.

    Policy Summary
    PayerBlue Cross Blue Shield - Illinois
    PolicyBiomarkers for Myocardial Infarction and Chronic Heart Failure
    Policy CodePolicy RPLAB046
    Change TypeAdministrative and reference updates only
    Effective DateDec 4, 202615d
    Next Review DateN/A
    Key ActionBill quantitative troponin only for qualifying acute coronary syndrome evaluation and limit potentially reimbursable testing to four times within the first 72 hours.
    SourceLink
    POLICY UPDATE CHANGES

    The document was updated and references were revised while reimbursement information remained unchanged.

    Up to 4Quantitative troponin measurements potentially reimbursable within the first 72 hours after acute coronary syndrome presentation
    Up to 4/yearOutpatient BNP or NT-proBNP measurements potentially reimbursable for chronic heart failure disease severity

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6Named legacy cardiac biomarkers not reimbursable for diagnosis or prognosis of myocardial infarction
    Not reimbursableOutpatient qualitative troponin measurement
    Not reimbursableOutpatient ST2 and its isoforms in all situations
    UnchangedReimbursement information

    Reimbursable and Excluded Biomarker Testing

    Potentially Reimbursable Biomarker Testing

    The following services may be reimbursable when the stated clinical and outpatient-setting criteria are met:

    ONE of the following

    • ALL of the following

      • Individual presents with signs and symptoms of acute coronary syndrome (see NOTE 1).
      • Quantitative measurement of cardiac troponin (troponin T or I) is performed for the diagnosis of myocardial infarction (MI).
      • Testing is performed at an outpatient facility capable of performing an adequate clinical MI evaluation.
    • BNP or NT-proBNP testing for ONE of the following indications

      • Diagnosis of heart failure in an individual presenting with dyspnea.
      • Establishment of disease severity in an individual with chronic heart failure in the outpatient setting.up to 4 times per year

    Excluded Biomarker Testing

    The following biomarker testing is not reimbursable under the stated circumstances:

    Any of the following exclusions

    • ALL of the following

      • Individual presents with signs and symptoms of acute coronary syndrome (see NOTE 1).
      • Measurement of the following cardiac biomarkers for the diagnosis and/or prognosis of MI

        • Aspartate aminotransferase (AST/SGOT).
        • Cardiac creatine kinase isoenzyme MB (CKMB).
        • Creatine kinase (CK).

    Covered and Noncovered Laboratory Codes

    Quantitative troponinCPTCovered
    84484ASSAY OF TROPONIN QUANT
    Natriuretic peptide testingCPTCovered
    83880ASSAY OF NATRIURETIC PEPTIDE
    Legacy myocardial infarction biomarkersCPTNot Covered
    82550ASSAY OF CK (CPK)
    82552ASSAY OF CPK IN BLOOD
    82553CREATINE MB FRACTION
    82554CREATINE ISOFORMS
    83615LACTATE (LD) (LDH) ENZYME
    83625ASSAY OF LDH ENZYMES
    83874ASSAY OF MYOGLOBIN
    84450TRANSFERASE (AST) (SGOT)
    Qualitative troponinCPTNot Covered
    84512ASSAY OF TROPONIN QUAL
    ST2 testingCPTNot Covered
    83006GROWTH STIMULATION GENE 2
    Other listed laboratory proceduresCPT
    82725ASSAY OF BLOOD FATTY ACIDS
    86140C-REACTIVE PROTEIN
    86141C-REACTIVE PROTEIN HS
    84999UNLISTED CHEMISTRY PROCEDURE
    84588ASSAY OF VASOPRESSIN
    Quantitative troponin frequency
    TestQuantitative cardiac troponin T or I
    Clinical useDiagnosis of myocardial infarction in individuals presenting with signs and symptoms of acute coronary syndrome
    Frequency limitUp to 4 times
    Timing limitWithin the first 72 hours following initial presentation
    Outpatient BNP or NT-proBNP frequency
    Test

    Claim Submission and Billing Guidance

    Documentation Required

    Submit Accurate Claims and Documentation

    Submit accurate documentation of services performed and use valid code combinations from HIPAA-approved code sets. Code claims according to applicable industry-standard coding guidelines, including CPT, HCPCS, ICD-10-CM/PCS, NDC, UB-04, DRG, NCCI, CCI edits, and other CMS guidance.

    Documentation Required

    Support Claims When Requested

    Claims may be subject to claim review and coding software edits. Upon request, provide any additional documentation supporting the services billed.

    Note

    Verify Product-Specific Requirements

    Not all reimbursement requirements apply to every product. Review the applicable Plan documents and product-specific coverage requirements before rendering and billing services.

    Clinical and Facility Definitions

    Acute coronary syndrome / myocardial infarction signs and symptoms
    Chest symptomsIschemic chest pain; squeezing, tightness, pressure, constriction, crushing, burning, heartburn, fullness, or a heavy weight in the chest
    Radiating painPain may radiate to the arms, upper abdomen (epigastrium), shoulders, neck, throat, lower jaw, teeth, or back
    Associated symptomsShortness of breath, belching, nausea, indigestion, vomiting, diaphoresis, dizziness, lightheadedness, clamminess, and fatigue
    Atypical presentationsDyspnea alone, weakness, nausea and/or vomiting, epigastric pain or discomfort, palpitations, syncope, or cardiac arrest
    Facility capable of adequate clinical MI evaluation
    Facility definitionAn outpatient facility capable of performing an adequate clinical myocardial infarction evaluation
    Policy Summary
    PayerBlue Cross Blue Shield - Illinois
    PolicyBiomarkers for Myocardial Infarction and Chronic Heart Failure
    Policy CodePolicy RPLAB046
    Change TypeAdministrative and reference updates only
    Effective DateDec 4, 202615d
    Next Review DateN/A
    Key ActionBill quantitative troponin only for qualifying acute coronary syndrome evaluation and limit potentially reimbursable testing to four times within the first 72 hours.
    SourceLink
    On This Page
    Reimbursable and Excluded Biomarker TestingCovered and Noncovered Laboratory CodesClaim Submission and Billing GuidanceClinical and Facility Definitions
    Creatine kinase isoenzymes.
  1. Lactate dehydrogenase (LD, LDH).
  2. Myoglobin.
  3. ALL of the following

    • Individual presents with signs and symptoms of acute coronary syndrome (see NOTE 1).
    • Cardiac biomarker measurement is performed in an outpatient setting that is not capable of performing an adequate clinical MI evaluation, including an independent laboratory or physician's office.
  4. Qualitative measurement of cardiac troponin (troponin T or I) in the outpatient setting.
  5. ALL of the following

    • Individual presents with signs and symptoms of acute coronary syndrome (see NOTE 1).
    • Measurement of the following cardiac biomarkers for the diagnosis and/or prognosis of MI

      • Copeptin.
      • Troponin C.
      • C-reactive protein.
      • Heart-type fatty acid binding protein (H-FABP).
      • Any other cardiac biomarkers not listed above.
  6. Analysis of ST2 and/or its isoforms, including Presage ST2, in any outpatient situation.
  7. BNP or NT-proBNP
    Chronic heart failure useEstablishing disease severity in individuals with chronic heart failure
    SettingOutpatient setting
    Annual frequency limitUp to 4 times per year
    Billing Rule

    Quantitative Troponin: Setting and Frequency

    For individuals presenting with signs and symptoms of acute coronary syndrome, quantitative cardiac troponin (troponin T or I) may be reimbursable for diagnosis of myocardial infarction when testing is performed at an outpatient facility capable of performing an adequate clinical myocardial infarction evaluation.

    • Testing may be reimbursable up to four times within the first 72 hours after initial presentation.
    • Testing performed in an outpatient setting that cannot perform an adequate clinical myocardial infarction evaluation, such as an independent laboratory or physician's office, is not reimbursable.
    Billing Rule

    BNP or NT-proBNP Indications

    BNP or NT-proBNP may be reimbursable when evaluating individuals presenting with dyspnea to diagnose heart failure or when establishing disease severity in individuals with chronic heart failure.

    • For chronic heart failure severity assessment in the outpatient setting, testing may be reimbursable up to four times per year.
    Denial Risk

    Avoid Nonreimbursable Biomarker Services

    Avoid billing nonreimbursable cardiac biomarker services in the specified outpatient and acute coronary syndrome settings. Qualitative troponin testing and testing performed where an adequate clinical myocardial infarction evaluation cannot be completed are not reimbursable.

    • For acute coronary syndrome presentations, AST/SGOT, CK-MB, CK, CK isoenzymes, LD/LDH, myoglobin, copeptin, troponin C, C-reactive protein, H-FABP, and other cardiac biomarkers not listed as reimbursable are not reimbursable for MI diagnosis or prognosis.
    • In all outpatient situations, analysis of ST2 or its isoforms, including Presage ST2, is not reimbursable.
    Applicable settingThe facility capability requirement applies when cardiac biomarker testing is performed for acute coronary syndrome evaluation
    Examples that may not qualifyIndependent laboratories and physician offices may not be capable of performing an adequate clinical myocardial infarction evaluation